Metronomic chemotherapy
ME Cazzaniga, N Cordani, S Capici, V Cogliati, F Riva… - Cancers, 2021 - mdpi.com
Simple Summary The present article reviews the state of the art of metronomic
chemotherapy use to treat the principal types of cancers, namely breast, non-small cell lung …
chemotherapy use to treat the principal types of cancers, namely breast, non-small cell lung …
Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised …
YP Chen, X Liu, Q Zhou, KY Yang, F Jin, XD Zhu, M Shi… - The Lancet, 2021 - thelancet.com
Background Patients with locoregionally advanced nasopharyngeal carcinoma have a high
risk of disease relapse, despite a high proportion of patients attaining complete clinical …
risk of disease relapse, despite a high proportion of patients attaining complete clinical …
Low-dose immunotherapy in head and neck cancer: a randomized study
PURPOSE The regimens approved for the treatment of advanced head and neck squamous
cell carcinoma are accessible to only 1%-3% of patients in low-and middle-income countries …
cell carcinoma are accessible to only 1%-3% of patients in low-and middle-income countries …
BOIN12: Bayesian optimal interval phase I/II trial design for utility-based dose finding in immunotherapy and targeted therapies
PURPOSE For immunotherapy, such as checkpoint inhibitors and chimeric antigen receptor
T-cell therapy, where the efficacy does not necessarily increase with the dose, the maximum …
T-cell therapy, where the efficacy does not necessarily increase with the dose, the maximum …
COVID-19 and head and neck cancer treatment
Abstract The coronavirus disease 2019 (COVID-19) pandemic is exponentially increasing,
as are the risks of COVID-related complications and fatalities. Hence, health-care resources …
as are the risks of COVID-related complications and fatalities. Hence, health-care resources …
Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label …
Background Regimens for palliation in patients with head and neck cancer recommended
by the US National Comprehensive Cancer Network (NCCN) have low applicability (less …
by the US National Comprehensive Cancer Network (NCCN) have low applicability (less …
Nivolumab in platinum-refractory head-and-neck cancers: A retrospective observational audit from a tertiary cancer center
VM Patil, H Muthuluri, J Choudhary… - Cancer Research …, 2022 - journals.lww.com
Background: Nivolumab and pembrolizumab are approved treatment options for platinum-
refractory head-and-neck squamous cell cancer (HNSCC) based on the demonstration of …
refractory head-and-neck squamous cell cancer (HNSCC) based on the demonstration of …
The pattern of care in head-and-neck cancer: Comparison between before and during the COVID-19 pandemic
Background: Coronavirus disease 2019 (COVID-19) has led to a redistribution of the
medical resources. However, there are limited data on the treatment patterns in head-and …
medical resources. However, there are limited data on the treatment patterns in head-and …
A mechanistic Review of methotrexate and celecoxib as a potential metronomic chemotherapy for oral squamous cell carcinoma
The combination of low-dose methotrexate and celecoxib as metronomic chemotherapy
(MCT) is a novel therapy, believed to act by modulating the immune response, inhibiting …
(MCT) is a novel therapy, believed to act by modulating the immune response, inhibiting …
Beyond conventional chemotherapy, targeted therapy and immunotherapy in squamous cell cancer of the oral cavity
The focus of this review article is to throw light on non-conventional systemic chemotherapy
that affects the tumour microenvironment and potentially has a favourable impact on the …
that affects the tumour microenvironment and potentially has a favourable impact on the …